BioCryst Pharmaceuticals (BCRX) Set to Announce Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is set to announce its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.11. The company had revenue of $109.30 million during the quarter, compared to analyst estimates of $98.30 million. The business’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.24) earnings per share. On average, analysts expect BioCryst Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $8.43 on Friday. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -11.55 and a beta of 1.88. The company’s fifty day moving average is $7.86 and its two-hundred day moving average is $6.90. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.88.

Analyst Upgrades and Downgrades

Several analysts have issued reports on BCRX shares. JMP Securities raised their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Barclays upped their target price on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 6th. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $14.17.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.